Brooke Vanlente
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 107 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 15.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $561, 4.9 times the $114 reported in 2021.
Across 107 payments — averaging $18.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$308
- AbbVie$223
- AstraZeneca$194
- Otsuka America Pharmaceutical, Inc.$173
- Pfizer$108
- Boehringer Ingelheim$105
- plus $843 from 21 others
What the payments were for
- Food & beverage$1,954100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 14 | $308 |
| AbbVie | 12 | $223 |
| AstraZeneca | 12 | $194 |
| Otsuka America Pharmaceutical, Inc. | 9 | $173 |
| Pfizer | 7 | $108 |
| Boehringer Ingelheim | 6 | $105 |
| Astellas Pharma US Inc | 4 | $87 |
| Lilly USA, LLC | 5 | $79 |
| Bayer | 5 | $76 |
| Exact Sciences | 4 | $72 |
| Dexcom, Inc. | 3 | $68 |
| GSK | 3 | $66 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $50 |
| Merck | 2 | $46 |
| E.r. Squibb & Sons, L.L.C. | 2 | $40 |
| Lundbeck LLC | 2 | $39 |
| Sanofi-aventis U.S. LLC | 2 | $31 |
| Daiichi Sankyo Inc. | 2 | $29 |
| Phathom Pharmaceuticals, Inc. | 2 | $27 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $22 |
| Cranial Technologies, Inc | 1 | $19 |
| Phadia US Inc. | 1 | $18 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| Verona Pharma, Inc. | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| Amgen | 1 | $14 |
| Alnylam Pharmaceuticals Inc. | 1 | $14 |
How this compares
$1,954 in reported general payments places this provider in the 80th percentile of 3,657 family providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 27 | $232 |
| Doxycycline Hyclate | 41 | $172 |
| Cephalexin | 41 | $120 |
| Azithromycin | 23 | $109 |
| Prednisone | 57 | $108 |
| Ciprofloxacin Hcl | 11 | $48 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 21 | $39 |
Paid to pharmacies, not to this prescriber.
Other family in Ionia
- Jayme HeimGrandville$663K
- Susan WolgamottBloomfield Township$327K
- Elisheva EllenbergDetroit$150K
- Sarah JohnsonFarmington Hills$119K
- Daniela MaximTroy$112K
- Kelsey PrinceGrand Rapids$87K
- Brent MillerFremont$66K
- Rachael CompeauFlint$62K
- David KocendaLapeer$49K
- Tracy RobertsonBay City$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.